Best Income Stocks To Watch For 2014

Editor’s Note: As a Tax Day special for this edition of Utility & Income, we’ve given our colleagues at our sister publication, MLP Profits, an opportunity to explain the basics of master limited partnerships (MLP), which offer high-yielding, tax-deferred payouts.

While Utility Forecaster includes a number of MLPs in our Portfolios as well as in How They Rate, our coverage of the MLP space is not exhaustive.

For investors interested in thorough coverage of this area, MLP Profits provides three portfolios (Conservative, Growth and Aggressive), as well as a monthly Sector Spotlight feature, which analyzes the top MLPs operating in a particular niche, and two Best Buys every month.

MLP Basics

The first MLP was formed by Apache Oil Company in 1981. In 1987, Congress legislated the rules for publicly traded partnerships, which required that at least 90 percent of an MLP�� income must come from qualified sources, such as real estate or natural resources. Section 613 of the tax code requires qualifying energy sources to be depletable resources or their derivatives such as crude oil, petroleum products, natural gas and coal.

Top 5 Companies To Watch In Right Now: NewLink Genetics Corp (NLNK)

NewLink Genetics Corporation (NewLink), incorporated on June 4, 1999, is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes biologic and small-molecule immunotherapy product candidates focused to treat a range of oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy (HyperAcute Pancreas), is being studied in a Phase-III clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA), with the United States Food and Drug Administration (FDA). It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy (HyperAcute Lung), which is being studied in a Phase-I/II clinical trial conducted at the National Cancer Institute (NCI), and its HyperAcute Melanoma cancer immunotherapy (HyperAcute Melanoma), which is being studied in an investigator-initiated Phase-II clinical trial.

The Company�� HyperAcute product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. It is also conducting small-molecule based research and development to produce new drugs capable of breaking the immune system's tolerance to cancer through inhibition of the indoleamine-(2,3)-dioxygenase (IDO), pathway. It is engaged in the study of IDO pathway inhibitor product candidate, d-1-methyltryptophan (D-1MT), in collaboration with the NCI, in two Phase 1B/II clinical trials.

HyperAcute Cancer Immunotherapy Product Candidates

In May 2010, the Company initiated Phase-III clinical trial for HyperAcute Pancreas. Its second product candidate, HyperAcute Lung, is in a Phase I/II clinical trial that is enrolled with 54 patients for the treatment of refractory, recurrent or metastatic nonresectable non-small cell lung cancer (NSCLC). Its Hyper! Acute Melanoma product candidate is being studied in an investigator-initiated, fully enrolled 25 patient Phase-II clinical trial for the treatment of advanced melanoma.

HyperAcute Cancer Immunotherapy Technology

The Company�� HyperAcute immunotherapies operate by exploiting a natural barrier present in humans that protects against infection being transmitted from other mammals. This barrier is related to the enzyme, alpha (1,3) galactosyl transferase, which is expressed in the cells of lower mammals. The presence of this enzyme results in the expression of a non-human form of carbohydrate called alpha (1,3) galactosyl carbohydrates (a-Gal), on the surface of affected cells. Its HyperAcute immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes a-Gal epitopes. This exposure to a-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on, which a-Gal is present by activating complement.

IDO Pathway Inhibitor Product Candidate

The Company is developing D-1MT, a small-molecule, orally bioavailable product candidate designed to inhibit the IDO pathway. In preclinical models, IDO pathway inhibitors have shown anti-tumor effects in combination with radiotherapy, chemotherapy, targeted therapy or immunotherapy. Through its collaboration with the NCI, it is studying D-1MT in two Phase 1B/II safety and efficacy clinical trials in various chemotherapy and immunotherapy combinations. One clinical trial combines D-1MT with an Ad-p53 autologous dendritic cell vaccine for solid malignancies with p53 mutations, such as lung, breast and colon cancers. The other clinical trial involves the combined use of D-1MT and Taxotere for patients with advanced stage solid tumors, for which Taxotere is the standard-of-care treatment, such as metastatic breast, prostate, ovarian and lung cancers.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  In trading on Thursday, healthcare shares were relative laggards, down on the day by about 0.64 percent. Top decliners in the sector included Sunesis Pharmaceuticals (NASDAQ: SNSS), off 5.6 percent, and NewLink Genetics (NASDAQ: NLNK), down 6.3 percent.

• [By Jayson Derrick]

  NewLink Genetics (NASDAQ: NLNK) announced that it will discontinue the phase 3 IMPRESS clinical trial of algenpantucel-L for patients with pancreatic cancer. The company intends to regroup and ��athering additional, more mature data in support of our mission to provide improved treatment options for patients with pancreatic cancer.��Shares fell 16.20 percent, closing at $31.60.

Best Income Stocks To Watch For 2014: Neuralstem Inc (CUR)

Neuralstem, Inc., incorporated in 1997, is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs. The Company has developed and maintains a portfolio of patents and patent applications that form base for its research and development efforts in the area of neural stem cell research. The Company's focus is the development of methods to generate replacement cells from neural stem cells.

In October of 2011, the Company announced that after reviewing safety data from the first 12 patients, the FDA granted approval for the trial to advance to transplanting patients in the cervical (upper back) region for the last six patients in the trial. As of December 31, 2011, the Company had treated 14 patients. In February of 2011, the Company commenced a Phase Ia clinical trial of its drug compound, NSI-189, which is being developed for the treatment of depressive disorder and other psychiatric indications. In October of 2011, the Company completed the Phase Ia portion of the trial. In December of 2011, the Company received approval from the FDA to commence the Phase Ib portion of the trial.

During the year ended December 31, 2011, the Company was selected as the primary subcontractor for the United States Department of Defense (DOD) contract to develop human neural stem cell technology for the treatment of cancerous brain tumors. The Company commenced work on the project in May 2011. The Company has developed and patented a series of small molecule compounds (low molecular weights organic compounds which can efficiently cross the blood/brain barrier).

Advisors' Opinion:

• [By John Udovich]

  Summer and the slow news for the market that usually comes with it�is over with and both stem cell researchers or small� cap stem cell stocks like Advanced Cell Technology, Inc (OTCBB: ACTC), Neuralstem, Inc (NYSEMKT: CUR), NeoStem Inc (NASDAQ: NBS), International Stem Cell Corp (OTCMKTS: ISCO)�and BioRestorative Therapies (OTCBB: BRTX) having news for investors and traders alike. Consider the following:

• [By GuruFocus]

  George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated

Best Income Stocks To Watch For 2014: R.R. Donnelley & Sons Company(RRD)

R.R. Donnelley & Sons Company provides pre-media, printing, logistics, and business process outsourcing products and services to private and public sectors worldwide. The company operates primarily in the commercial print portion of the printing industry, with related product and service offerings designed to offer customers solutions for communicating their messages to target audiences. Its products and related service offerings include magazines, catalogs, retail inserts, books, directories, financial print, direct mail, forms, labels, office products, statement printing, pre media, and logistics services. The company also offers business process outsourcing services that comprise transactional print and outsourcing services, statement printing, direct mail, and print management services; and product configuration, customized kitting, and order fulfillment for technology, medical device, and other companies. It distributes its products to end-users through the United Sta tes postal services, retail channels, electronically, or by direct shipment to customer facilities. R.R. Donnelley & Sons was founded in 1864 and is based in Chicago, Illinois.

Advisors' Opinion:

• [By Selena Maranjian]

  Commercial printer R.R. Donnelley (NASDAQ: RRD  ) , also up 28%, yields 7.3%. It sells labels, packaging, and more to the private and public sector and prints many thousands of forms for the SEC, too. Donnelley bought Edgar Online last year. Some have worried about the company's debt load, though it is free-cash-flow positive. (But it has posted net losses in recent years, too.) The company needs to do more digital business to succeed, which explains a recent eBook deal with Harlequin.

• [By Dan Burrows]

  R.R. Donnelley (RRD)

  RRD Price/LFCF: 9.4
  RRD Dividend Yield: 6.7%

  It’s hard to find a more boring company than R.R. Donnelley (RRD). It both prints and creates custom content (e.g., annual reports) for private and public companies.

• [By Eric Volkman]

  RR Donnelley (NASDAQ: RRD  ) will pay a quarterly dividend of $0.26 per share of its common stock on June 3 to shareholders of record as of April 26, the company announced this week.

Best Income Stocks To Watch For 2014: Muenchener Rueckversicherungs Gesellschaft AG in Muenchen (MUV2)

Muenchener Rueckversicherungs Gesellschaft AG in Muenchen is a Germany-based holding company engaged in reinsurance and insurance business fields. The Company diversifies its operations into reinsurance, primary insurance, Munich Health and Asset management. The Reinsurance business comprises five divisions: Life; Europe and Latin America; Germany, Asia Pacific and Africa; Special and Financial Risks, and Global Clients and North America. The business covers a range of products from traditional reinsurance products to solutions for risk assumption. The Company's primary insurance activities are combined into the ERGO Insurance Group (ERGO) and offers direct insurance, life, property-casualty, health, legal expenses and travel insurance products. It covers the Company's international health reinsurance business and health primary insurance outside Germany and engages the risk management services. The Asset management business handles the investment activities of Munich Re and ERGO. Advisors' Opinion:

• [By Jonathan Morgan]

  Munich Re (MUV2), the world�� biggest reinsurer, dropped 4.9 percent to 145.25 euros after it said second-quarter profit fell 35 percent, missing analysts��estimates, as claims arising from natural disasters rose. Net income dropped to 529 million euros from 808 million euros a year earlier, trailing the 557.1 million-euro average estimate of analysts surveyed by Bloomberg.